Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer
2
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
5